Kenji Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenji Nakamura has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Kazutoshi Okubo
Department of Urology Osaka Red Cross Hospital Osaka Japan
4 shared publications- Takashi Kobayashi
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
4 shared publications Koji Yoshimura
The Department of Urology, Kyoto University Graduate School of Medicine
3 shared publicationsMasaaki Imamura
The Department of Urology, Kyoto University Graduate School of Medicine
3 shared publicationsNaoki Terada
The Department of Urology, Kyoto University Graduate School of Medicine
3 shared publicationsTakayuki Goto
Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Harnessing Lung-Kidney Crosstalk: A Novel Ex Vivo Platform for Donor Lung Rehabilitation
- 11 November 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessHarnessing Lung-Kidney Crosstalk: A Novel Ex Vivo Platform for Donor Lung Rehabilitation
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (9) , e1993
10 °C Storage for the Preservation of Pig Kidney Grafts: A Porcine Autotransplant Model
Background.: Optimization of organ storage is essential to improve outcomes in kidney transplantation. Recent studies in lung transplantation highlight the impact of temperature on organ preservation, leading to a shift from traditional 4 °C “on-ice” storage toward 10 °C. We sought to determine whether these findings extend to kidney transplantation using 2 distinct porcine autotransplant models. Methods.: The initial donation after circulatory death model consisted of 30 min of warm ischemia followed by a brief 7.5 h storage on-ice (n = 5) or at 10 °C (n = 5). Grafts were retransplanted, the contralateral kidney was removed, and participants were followed up for 3 d. A second model simulating donation after brain death compared 24-h storage at 10 °C (n = 3) to a contemporaneous standard ice storage cohort (n = 3), followed by transplant, contralateral nephrectomy, and 7-d follow-up. Results.: The first model revealed discrete differences in creatinine, blood urea nitrogen, sodium, potassium, urine output, creatinine clearance, and fractional sodium excretion favoring 10 °C ( P > 0.05). Histology revealed reduced tubular injury ( P = 0.03) and interstitial inflammation ( P < 0.05) in the 10 °C group. Urinary neutrophil gelatin-associated lipocalin and thiobarbituric acid reactive substances were also reduced at 10 °C in the postoperative period ( P > 0.05). However, prolonged 24-h storage at 10 °C did not benefit kidney function, with significantly worse creatinine and blood urea nitrogen values over time ( P < 0.05). Conclusions.: The results of this initial study suggest that 10 °C storage may offer a modest protective effect in a short-storage porcine donation after circulatory death autotransplantation model; however, no benefit was demonstrated with prolonged storage, suggesting that any potential effects may be organ- and preservation solution-specific, as well as time-dependent. Larger studies are needed to draw more definitive conclusions.
- 21 August 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (9) , e1993
Open Access10 °C Storage for the Preservation of Pig Kidney Grafts: A Porcine Autotransplant Model
Background.: Optimization of organ storage is essential to improve outcomes in kidney transplantation. Recent studies in lung transplantation highlight the impact of temperature on organ preservation, leading to a shift from traditional 4 °C “on-ice” storage toward 10 °C. We sought to determine whether these findings extend to kidney transplantation using 2 distinct porcine autotransplant models. Methods.: The initial donation after circulatory death model consisted of 30 min of warm ischemia followed by a brief 7.5 h storage on-ice (n = 5) or at 10 °C (n = 5). Grafts were retransplanted, the contralateral kidney was removed, and participants were followed up for 3 d. A second model simulating donation after brain death compared 24-h storage at 10 °C (n = 3) to a contemporaneous standard ice storage cohort (n = 3), followed by transplant, contralateral nephrectomy, and 7-d follow-up. Results.: The first model revealed discrete differences in creatinine, blood urea nitrogen, sodium, potassium, urine output, creatinine clearance, and fractional sodium excretion favoring 10 °C ( P > 0.05). Histology revealed reduced tubular injury ( P = 0.03) and interstitial inflammation ( P < 0.05) in the 10 °C group. Urinary neutrophil gelatin-associated lipocalin and thiobarbituric acid reactive substances were also reduced at 10 °C in the postoperative period ( P > 0.05). However, prolonged 24-h storage at 10 °C did not benefit kidney function, with significantly worse creatinine and blood urea nitrogen values over time ( P < 0.05). Conclusions.: The results of this initial study suggest that 10 °C storage may offer a modest protective effect in a short-storage porcine donation after circulatory death autotransplantation model; however, no benefit was demonstrated with prolonged storage, suggesting that any potential effects may be organ- and preservation solution-specific, as well as time-dependent. Larger studies are needed to draw more definitive conclusions.
- Open Access
- 1 September 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (6) , 558-562
Tuberculous Retroperitoneal Lymphadenitis After Kidney Transplantation That Was Difficult to Diagnose and Treat: A Case Report
Introduction: We present a rare case of tuberculous retroperitoneal lymphadenitis after kidney transplantation that was difficult to diagnose and treat. Case Presentation: A 52‐year‐old man who received a kidney transplantation from his wife presented with right lower quadrant pain. Computed tomography (CT) scan revealed multiple enlarged retroperitoneal lymph nodes, which later formed abscesses. From the positive Mycobacterium tuberculosis polymerase chain reaction test and smear in the drainage fluid, he was diagnosed with tuberculosis. Despite treatment with antituberculosis drugs, the abscesses increased, and he was treated by open drainage. He showed gradual clinical improvement and was discharged 9 weeks after hospitalization. While an abscess around the pancreatic tail remained, he was in remission, and antituberculosis drugs were terminated 404 days after initiation. He has gone 1 year without recurrence. Conclusion: Tuberculous lymphadenitis after kidney transplantation is a rare condition but should be kept in mind for accurate diagnosis.
- 1 September 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (6) , 558-562
Open AccessTuberculous Retroperitoneal Lymphadenitis After Kidney Transplantation That Was Difficult to Diagnose and Treat: A Case Report
Introduction: We present a rare case of tuberculous retroperitoneal lymphadenitis after kidney transplantation that was difficult to diagnose and treat. Case Presentation: A 52‐year‐old man who received a kidney transplantation from his wife presented with right lower quadrant pain. Computed tomography (CT) scan revealed multiple enlarged retroperitoneal lymph nodes, which later formed abscesses. From the positive Mycobacterium tuberculosis polymerase chain reaction test and smear in the drainage fluid, he was diagnosed with tuberculosis. Despite treatment with antituberculosis drugs, the abscesses increased, and he was treated by open drainage. He showed gradual clinical improvement and was discharged 9 weeks after hospitalization. While an abscess around the pancreatic tail remained, he was in remission, and antituberculosis drugs were terminated 404 days after initiation. He has gone 1 year without recurrence. Conclusion: Tuberculous lymphadenitis after kidney transplantation is a rare condition but should be kept in mind for accurate diagnosis.
- Open Access
- 22 February 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (19) , 1336-1349
PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations
Despite missense mutation accounts for over 60% of p53 alterations while homozygous deletion (HOM) for only 5% or less in advanced bladder cancer cases, most of the previously reported mouse models are deficient of p53. Accordingly, few studies have addressed the mechanisms of missense mutation occurrence and its functional advantage over HOM in bladder cancer development. Organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) demonstrated the crucial role of Pten loss in driving loss of wild-type allele of Trp53 (Trp53 R172H/LOH ), which conferred tumorigenic ability to K5-mUrorganoid in athymic mice. These tumors recapitulated the histological and genetic characteristics of the human basal-squamous subtype bladder cancer. Both Trp53 R172H/Δ ; Pten Δ/Δ and Trp53 Δ/Δ ; Pten Δ/Δ K5-mUrorganoids formed tumors in athymic mice, whereas only Trp53 R172H/Δ ; Pten Δ/Δ K5-mUrorganoid formed tumors even when directly inoculated in immunocompetent syngeneic mice. The absence of wild-type Trp53 was associated with upregulation of proliferative signaling, and the presence of a mutant Trp53 allele was associated with immune-excluded microenvironment. This study highlights the functional significance of p53 mutant LOH in bladder carcinogenesis conferring several hallmarks of cancer such as sustaining proliferative signaling and avoiding immune destruction, thus provides a novel immunocompetent mouse model of urothelial carcinoma harboring p53 mutations as a novel tool for cancer immunology research.
- 22 February 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (19) , 1336-1349
Open AccessPTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations
Despite missense mutation accounts for over 60% of p53 alterations while homozygous deletion (HOM) for only 5% or less in advanced bladder cancer cases, most of the previously reported mouse models are deficient of p53. Accordingly, few studies have addressed the mechanisms of missense mutation occurrence and its functional advantage over HOM in bladder cancer development. Organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) demonstrated the crucial role of Pten loss in driving loss of wild-type allele of Trp53 (Trp53 R172H/LOH ), which conferred tumorigenic ability to K5-mUrorganoid in athymic mice. These tumors recapitulated the histological and genetic characteristics of the human basal-squamous subtype bladder cancer. Both Trp53 R172H/Δ ; Pten Δ/Δ and Trp53 Δ/Δ ; Pten Δ/Δ K5-mUrorganoids formed tumors in athymic mice, whereas only Trp53 R172H/Δ ; Pten Δ/Δ K5-mUrorganoid formed tumors even when directly inoculated in immunocompetent syngeneic mice. The absence of wild-type Trp53 was associated with upregulation of proliferative signaling, and the presence of a mutant Trp53 allele was associated with immune-excluded microenvironment. This study highlights the functional significance of p53 mutant LOH in bladder carcinogenesis conferring several hallmarks of cancer such as sustaining proliferative signaling and avoiding immune destruction, thus provides a novel immunocompetent mouse model of urothelial carcinoma harboring p53 mutations as a novel tool for cancer immunology research.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400472
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer
PURPOSE: Circulating tumor DNA (ctDNA) analysis is an alternative to tissue biopsy for genotyping in various cancers. We aimed to establish a plasma ctDNA sequencing assay, then evaluate its clinical utility in advanced urothelial cancer (UC). MATERIALS AND METHODS: This study included 82 patients with muscle-invasive or metastatic UC. A total of 158 blood samples and 73 tumor tissue samples were sequenced using our designed panel covering 53 UC-relevant genes and TERT promoter. We investigated the association between the proportion of ctDNA in total cell-free DNA (ctDNA fraction) and response to pembrolizumab treatment. ctDNA dynamics were explored during systemic therapy. RESULTS: In paired tissue-ctDNA samples with estimated tumor fraction, half (50.2%) of the somatic mutations were shared between both sources, while some (17.6%) mutations were found only in ctDNA. In the metastatic setting, on-treatment increase in ctDNA fraction during pembrolizumab treatment was significantly associated with a poor response rate (18.7% v 76.1%; P = .001) and progression-free survival (median 2.8 v 9.8 months; P < .001). A comparison of cancer cell fraction, the fraction of tumor cells carrying somatic mutations, between pembrolizumab initiation and on-treatment showed a strong correlation among patients where ctDNA fraction increased during treatment ( r = 0.73). By contrast, no correlation was observed in patients without ctDNA fraction increase ( r = 0.09). Most mutations newly detected at pembrolizumab resistance have already been identified in tumor tissues at earlier stages. CONCLUSION: Our newly established assay is suitable for assessing the genomic profile of ctDNA in patients with advanced UC. Our data may support future analyses of prognostic or predictive biomarkers for UC.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400472
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer
PURPOSE: Circulating tumor DNA (ctDNA) analysis is an alternative to tissue biopsy for genotyping in various cancers. We aimed to establish a plasma ctDNA sequencing assay, then evaluate its clinical utility in advanced urothelial cancer (UC). MATERIALS AND METHODS: This study included 82 patients with muscle-invasive or metastatic UC. A total of 158 blood samples and 73 tumor tissue samples were sequenced using our designed panel covering 53 UC-relevant genes and TERT promoter. We investigated the association between the proportion of ctDNA in total cell-free DNA (ctDNA fraction) and response to pembrolizumab treatment. ctDNA dynamics were explored during systemic therapy. RESULTS: In paired tissue-ctDNA samples with estimated tumor fraction, half (50.2%) of the somatic mutations were shared between both sources, while some (17.6%) mutations were found only in ctDNA. In the metastatic setting, on-treatment increase in ctDNA fraction during pembrolizumab treatment was significantly associated with a poor response rate (18.7% v 76.1%; P = .001) and progression-free survival (median 2.8 v 9.8 months; P < .001). A comparison of cancer cell fraction, the fraction of tumor cells carrying somatic mutations, between pembrolizumab initiation and on-treatment showed a strong correlation among patients where ctDNA fraction increased during treatment ( r = 0.73). By contrast, no correlation was observed in patients without ctDNA fraction increase ( r = 0.09). Most mutations newly detected at pembrolizumab resistance have already been identified in tumor tissues at earlier stages. CONCLUSION: Our newly established assay is suitable for assessing the genomic profile of ctDNA in patients with advanced UC. Our data may support future analyses of prognostic or predictive biomarkers for UC.
- Open Access
IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
Although immune checkpoint inhibitors have shown benefit for advanced urothelial carcinoma (aUC) patients, prognostication of treatment efficacy and response duration remains a clinical challenge. We evaluated the expression of immune markers in the tumor microenvironment and assessed their associations with response to and survival after pembrolizumab treatment in 26 aUC patients. High levels of CD8+ tumor-infiltrating lymphocytes (TILs) were associated with favorable objective responses (23.0% vs. 15.3%, p = 0.0425), progression-free survival (median, 8.8 vs 2.1 months; hazard ratio (HR), 0.24; 95% confidence interval (CI), 0.07–0.66, p = 0.0060), and overall survival (median, >24.0 vs. 5.3 months; HR, 0.17; 95% CI, 0.04–0.56, p = 0.0034) compared with low levels. High interferon-gamma (IFNγ) expression levels were associated with longer post-progression survival (median, 4.9 vs. 1.0 months; HR, 0.18; 95% CI, 0.04–0.59, p = 0.0027) compared with low expression. Multivariate analysis incorporating clinical prognosticators demonstrated that the coincidence of low CD8+ T cells/IFNγ was an independent factor for unfavorable overall survival after pembrolizumab treatment (HR, 4.07; 95% CI, 1.36–12.73; p = 0.0125). The combination of low CD8+ TILs and IFNγ expression was an independent prognostic factor with predictive ability equivalent to previously reported clinical prognosticators.
Open AccessIFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
Although immune checkpoint inhibitors have shown benefit for advanced urothelial carcinoma (aUC) patients, prognostication of treatment efficacy and response duration remains a clinical challenge. We evaluated the expression of immune markers in the tumor microenvironment and assessed their associations with response to and survival after pembrolizumab treatment in 26 aUC patients. High levels of CD8+ tumor-infiltrating lymphocytes (TILs) were associated with favorable objective responses (23.0% vs. 15.3%, p = 0.0425), progression-free survival (median, 8.8 vs 2.1 months; hazard ratio (HR), 0.24; 95% confidence interval (CI), 0.07–0.66, p = 0.0060), and overall survival (median, >24.0 vs. 5.3 months; HR, 0.17; 95% CI, 0.04–0.56, p = 0.0034) compared with low levels. High interferon-gamma (IFNγ) expression levels were associated with longer post-progression survival (median, 4.9 vs. 1.0 months; HR, 0.18; 95% CI, 0.04–0.59, p = 0.0027) compared with low expression. Multivariate analysis incorporating clinical prognosticators demonstrated that the coincidence of low CD8+ T cells/IFNγ was an independent factor for unfavorable overall survival after pembrolizumab treatment (HR, 4.07; 95% CI, 1.36–12.73; p = 0.0125). The combination of low CD8+ TILs and IFNγ expression was an independent prognostic factor with predictive ability equivalent to previously reported clinical prognosticators.
- Open Access
- 11 December 2020
- Published by Wiley in IJU Case Reports
- Vol. 4 (2) , 79-81
Successful surgical resection and reconstruction of scrotal elephantiasis
Introduction: An enlarged scrotum due to scrotal elephantiasis results in a poor quality of life. This condition is uncommon and challenging to manage for most urologists. We report a case of scrotal elephantiasis treated with resection and scrotal reconstruction.Case presentation: A 57‐year‐old man was referred to our hospital with a 6‐year history of scrotal swelling. The scrotum was 20 cm in diameter, stiff, and thick. He was diagnosed with chronic scrotal lymphedema and underwent scrotal resection. The skin and subcutaneous tissues of the scrotum were excised, and the suprapubic skin, which was stretched by the enlarged scrotum, was used for the scrotal reconstruction. The penis was pulled out from this hole in the skin.Conclusion: Utilizing suprapubic skin flap for scrotal reconstruction is an effective treatment for scrotal elephantiasis that can result in functionally and cosmetically successful outcomes.
- 11 December 2020
- Published by Wiley in IJU Case Reports
- Vol. 4 (2) , 79-81
Open AccessSuccessful surgical resection and reconstruction of scrotal elephantiasis
Introduction: An enlarged scrotum due to scrotal elephantiasis results in a poor quality of life. This condition is uncommon and challenging to manage for most urologists. We report a case of scrotal elephantiasis treated with resection and scrotal reconstruction.Case presentation: A 57‐year‐old man was referred to our hospital with a 6‐year history of scrotal swelling. The scrotum was 20 cm in diameter, stiff, and thick. He was diagnosed with chronic scrotal lymphedema and underwent scrotal resection. The skin and subcutaneous tissues of the scrotum were excised, and the suprapubic skin, which was stretched by the enlarged scrotum, was used for the scrotal reconstruction. The penis was pulled out from this hole in the skin.Conclusion: Utilizing suprapubic skin flap for scrotal reconstruction is an effective treatment for scrotal elephantiasis that can result in functionally and cosmetically successful outcomes.
- Open Access
- 26 November 2018
- Published by Wiley in IJU Case Reports
- Vol. 2 (1) , 30-33
Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
Introduction: A radiation recall reaction in previously irradiated lungs is known as radiation recall pneumonitis. We encountered a rare case of radiation recall pneumonitis induced by nivolumab 9 months after palliative radiotherapy to the ribs.Case presentation: The patient was a 69‐year‐old woman with renal cell carcinoma. She had received various drugs and palliative irradiation, which was followed by nivolumab treatment, for renal cell carcinoma. Three days after the initial nivolumab administration, she presented with respiratory symptoms. On the basis of chest computed tomography findings, she was diagnosed with nivolumab‐induced radiation recall pneumonitis and treated with prednisolone (1 mg/kg). The condition resolved rapidly, and chest computed tomography 4 months after nivolumab cessation revealed interval resolution of the lung consolidation and persistent tumor shrinkage.Conclusion: Physicians should consider the risk of radiation recall pneumonitis during treatment with immune checkpoint inhibitors in patients who have received previous thoracic radiotherapy.
- 26 November 2018
- Published by Wiley in IJU Case Reports
- Vol. 2 (1) , 30-33
Open AccessRadiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
Introduction: A radiation recall reaction in previously irradiated lungs is known as radiation recall pneumonitis. We encountered a rare case of radiation recall pneumonitis induced by nivolumab 9 months after palliative radiotherapy to the ribs.Case presentation: The patient was a 69‐year‐old woman with renal cell carcinoma. She had received various drugs and palliative irradiation, which was followed by nivolumab treatment, for renal cell carcinoma. Three days after the initial nivolumab administration, she presented with respiratory symptoms. On the basis of chest computed tomography findings, she was diagnosed with nivolumab‐induced radiation recall pneumonitis and treated with prednisolone (1 mg/kg). The condition resolved rapidly, and chest computed tomography 4 months after nivolumab cessation revealed interval resolution of the lung consolidation and persistent tumor shrinkage.Conclusion: Physicians should consider the risk of radiation recall pneumonitis during treatment with immune checkpoint inhibitors in patients who have received previous thoracic radiotherapy.
- 1 January 2016
- Vol. 62 (1) , 39-44
[A Case of Bisphosphonate-Related Osteonecrosis of the Jaw with Difficulty in Treatment].
A 65-year-old man with urination difficulty visited our hospital. Because his prostate-specific antigen level was 1,619 ng/ml, we performed a prostate biopsy. The biopsy specimen yielded a diagnosis of adenocarcinoma with a Gleason score of 4+4. Computed tomography and bone scintigraphy showed lymph node, lung, and bone metastasis (cT3bN1M1). After 13 months of combined androgen blockade, he underwent treatment with a bisphosphonate. At 22 months of treatment, he developed bisphosphonate-related osteonecrosis of the jaw, and all necrotic bone and teeth were removed. He subsequently underwent repeated cleaning and fixation (splinting) for an oral fistula and mandibular fracture. Emergency transcatheter arterial embolization was then performed to treat a bleeding of the facial artery aneurysm. An oral infection and aspiration pneumonia repeatedly developed secondary to the oral fistula. The patient underwent a gastrostomy, after which his nutritional status improved and he was discharged.
- 1 January 2016
- Vol. 62 (1) , 39-44
[A Case of Bisphosphonate-Related Osteonecrosis of the Jaw with Difficulty in Treatment].
A 65-year-old man with urination difficulty visited our hospital. Because his prostate-specific antigen level was 1,619 ng/ml, we performed a prostate biopsy. The biopsy specimen yielded a diagnosis of adenocarcinoma with a Gleason score of 4+4. Computed tomography and bone scintigraphy showed lymph node, lung, and bone metastasis (cT3bN1M1). After 13 months of combined androgen blockade, he underwent treatment with a bisphosphonate. At 22 months of treatment, he developed bisphosphonate-related osteonecrosis of the jaw, and all necrotic bone and teeth were removed. He subsequently underwent repeated cleaning and fixation (splinting) for an oral fistula and mandibular fracture. Emergency transcatheter arterial embolization was then performed to treat a bleeding of the facial artery aneurysm. An oral infection and aspiration pneumonia repeatedly developed secondary to the oral fistula. The patient underwent a gastrostomy, after which his nutritional status improved and he was discharged.
- 1 December 2015
- Vol. 61 (12) , 487-91
[Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital].
Prostate ductal adenocarcinoma is a rare variant of prostate cancer and considered to be more aggressive than the common acinar type of adenocarcinoma. The appropriate treatment guideline for prostate ductal adenocarcinoma has not been established. The aim of the present study was to examine the clinical characteristics and the effectiveness of treatment for prostate ductal adenocarcinoma. From 2005 to 2012, 41 patients were diagnosed to have prostate ductal adenocarcinoma in Kyoto University Hospital. The mean±SD age was 68.6±7.0 years, and the median (range) initial serum PSA level was 9.3 (3.7-217) ng/ml. Among 17 patients who underwent radical prostatectomy, 10 (58.8%) had pT3 disease and 5 (29.4%) had biochemical recurrence during median follow-up of 22.9 months. Out of 19 patients treated with definitive EBRT with endocrine therapy, 2 patients (10.5%) experienced biochemical recurrence with median follow-up of 37.3 months. Five patients were treated with endocrine therapy alone, and 2 (40.0%) of them died of prostate ductal adenocarcinoma. In conclusion, patients with prostate ductal adenocarcinoma were more likely diagnosed as locally advanced diseases than those with prostate acinar adenocarcinoma. However, for patients without metastasis, either surgery or EBRT with endocrine therapy is effective with good prognosis.
- 1 December 2015
- Vol. 61 (12) , 487-91
[Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital].
Prostate ductal adenocarcinoma is a rare variant of prostate cancer and considered to be more aggressive than the common acinar type of adenocarcinoma. The appropriate treatment guideline for prostate ductal adenocarcinoma has not been established. The aim of the present study was to examine the clinical characteristics and the effectiveness of treatment for prostate ductal adenocarcinoma. From 2005 to 2012, 41 patients were diagnosed to have prostate ductal adenocarcinoma in Kyoto University Hospital. The mean±SD age was 68.6±7.0 years, and the median (range) initial serum PSA level was 9.3 (3.7-217) ng/ml. Among 17 patients who underwent radical prostatectomy, 10 (58.8%) had pT3 disease and 5 (29.4%) had biochemical recurrence during median follow-up of 22.9 months. Out of 19 patients treated with definitive EBRT with endocrine therapy, 2 patients (10.5%) experienced biochemical recurrence with median follow-up of 37.3 months. Five patients were treated with endocrine therapy alone, and 2 (40.0%) of them died of prostate ductal adenocarcinoma. In conclusion, patients with prostate ductal adenocarcinoma were more likely diagnosed as locally advanced diseases than those with prostate acinar adenocarcinoma. However, for patients without metastasis, either surgery or EBRT with endocrine therapy is effective with good prognosis.